A Bayesian dose-finding design for drug combination clinical trials based on the logistic model

Archive ouverte

Riviere, Marie-Karelle | Yuan, Ying | Dubois, Frédéric | Zohar, Sarah

Edité par CCSD ; Wiley -

International audience. In early phase dose-finding cancer studies, the objective is to determine the maximum tolerated dose, defined as the highest dose with an acceptable dose-limiting toxicity rate. Finding this dose for drug-combination trials is complicated because of drug–drug interactions, and many trial designs have been proposed to address this issue. These designs rely on complicated statistical models that typically are not familiar to clinicians, and are rarely used in practice. The aim of this paper is to propose a Bayesian dose-finding design for drug combination trials based on standard logistic regression. Under the proposed design, we continuously update the posterior estimates of the model parameters to make the decisions of dose assignment and early stopping. Simulation studies show that the proposed design is competitive and outperforms some existing designs. We also extend our design to handle delayed toxicities. Copyright © 2014 John Wiley & Sons, Ltd.

Suggestions

Du même auteur

Comments on ‘A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies’

Archive ouverte | Riviere, Marie-Karelle | CCSD

International audience

Response to comments on ‘Competing designs for drug combination in phase I dose-finding clinical trials’ by G. Yin, R. Lin and N. Wages

Archive ouverte | Riviere, Marie-Karelle | CCSD

International audience. As pointed out by Yin and Lin, and Wages, designs for drug-combination trials need to be rigorously evaluated. In our paper, we performed an extensive sensitivity analysis (with some of the r...

Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization

Archive ouverte | Riviere, Marie-Karelle | CCSD

International audience. Conventionally, phase I dose-finding trials aim to determine the maximum tolerated dose of a new drug under the assumption that both toxicity and efficacy monotonically increase with the dose...

Chargement des enrichissements...